<DOC>
	<DOCNO>NCT00003532</DOCNO>
	<brief_summary>RATIONALE : Antineoplastons naturally-occurring substance may also make laboratory . Antineoplastons may inhibit growth cancer cell . PURPOSE : This phase II trial study effectiveness antineoplaston therapy treat patient stage III stage IV ovarian cancer</brief_summary>
	<brief_title>Antineoplaston Therapy Treating Patients With Stage III Stage IV Ovarian Cancer</brief_title>
	<detailed_description>OBJECTIVES : - Study safety possible effectiveness antineoplastons A10 AS2-1 patient incurable stage III IV ovarian cancer . - Describe response , tolerance , side effect regimen patient population . OUTLINE : This open-label study . Patients receive gradually escalate dos antineoplaston A10 antineoplaston AS2-1 intravenous injection 6 time daily maximum tolerate dose level reach . Treatment continue least 3 month absence unacceptable toxicity disease progression . Patients achieve complete response ( CR ) continue treatment additional 8 month achieve CR . Tumors measure every 2 month 1 year every 3 month 1 year . PROJECTED ACCRUAL : A total 20-40 patient accrue study .</detailed_description>
	<mesh_term>Ovarian Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm stage III IV epithelial germ cell ovarian cancer unlikely respond exist therapy curative therapy exist Measurable disease CT scan MRI PATIENT CHARACTERISTICS : Age : 18 Performance status : Karnofsky 60100 % Life expectancy : At least 2 month Hematopoietic : WBC least 2,000/mm^3 Platelet count least 50,000/mm^3 Hepatic : Bilirubin great 2.5 mg/dL SGOT/SGPT great 5 time upper limit normal No hepatic failure Renal : Creatinine great 2.5 mg/mL No renal insufficiency No history renal condition contraindicate high dosage sodium Cardiovascular : No uncontrolled hypertension No history congestive heart failure No cardiovascular condition contraindicate high dosage sodium Pulmonary : No serious lung disease ( e.g. , chronic obstructive pulmonary disease ) Other : Not pregnant nursing Fertile patient must use effective contraception 4 week , , 4 week study participation No active infection No concurrent serious systemic disease PRIOR CONCURRENT THERAPY : Biologic therapy : At least 4 week since prior immunotherapy recover No concurrent immunomodulating agent Chemotherapy : At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) recover Endocrine therapy : Concurrent corticosteroid allow ( e.g. , dexamethasone methylprednisone ) Radiotherapy : At least 8 week since prior radiotherapy recover Surgery : Recovered prior surgery Other : Prior cytodifferentiating agent allow No prior antineoplaston therapy No concurrent antineoplastic agent</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2004</verification_date>
	<keyword>stage III ovarian epithelial cancer</keyword>
	<keyword>stage IV ovarian epithelial cancer</keyword>
	<keyword>recurrent ovarian epithelial cancer</keyword>
	<keyword>stage III ovarian germ cell tumor</keyword>
	<keyword>stage IV ovarian germ cell tumor</keyword>
	<keyword>recurrent ovarian germ cell tumor</keyword>
</DOC>